Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
03/2003
03/20/2003WO2002080669A3 Use of alpha2-adrenergic receptor agonists and adrenergic inhibitors in reducing defoliation
03/20/2003WO2002079404A3 Cytoskeleton-associated proteins
03/20/2003WO2002077290A9 Methods for modifying pharmacokinetics and bioavailability of exogenous compounds
03/20/2003WO2002077184A3 Oligonucleotide conjugates
03/20/2003WO2002075025A3 Process for preparing low defect density silicon using high growth rates
03/20/2003WO2002074910A3 Selective anti-viral nucleoside chain terminators
03/20/2003WO2002074758A3 Novel amines as histamine-3 receptor ligands and their therapeutic applications
03/20/2003WO2002067951A3 Use of 5-substituted nucleosides and/or prodrugs thereof in the resistance-free treatment of infectious diseases
03/20/2003WO2002067886A3 Skin composition
03/20/2003WO2002067885A3 Photoprotecting formulations
03/20/2003WO2002067865A3 N-(aryl)-2-arylethenesulfonamides and therapeutic uses thereof
03/20/2003WO2002066040A8 Sensitization of chemotherapeutic agent resistant neoplastic cells with reovirus
03/20/2003WO2002062323A3 Use of mglur5 antagonists for the treatment of pruritic conditions
03/20/2003WO2002060452A3 Use of carbohydrates for eliminating intestinal infections in animals
03/20/2003WO2002060393A3 Proteoglycan compositions for treatment of inflammatory conditions
03/20/2003WO2002060373A3 Indole derivatives and their uses as heparanase inhibitors
03/20/2003WO2002053733A3 Regulation of human b7-h2 protein
03/20/2003WO2002053171A3 Use of intermediate-conductance potassium channels and modulators for the diagnosis and treatment of illnesses having disturbed keratinocyte activity
03/20/2003WO2002049606A3 Transdermal systems (tds) that contain inhibitors of phosphodiesterase iv
03/20/2003WO2002047688A3 Method and apparatus for treating breakthrough pain
03/20/2003WO2002046189A3 Aryl ether substituted imidazoquinolines
03/20/2003WO2002041832A8 Compositions having comfrey and methods for reducing retinoid-induced skin irritation
03/20/2003WO2002039996A3 Combined therapy against tumors comprising estramustine phosphate and lhrh agonists or antagonists
03/20/2003WO2002032412A3 Combination use of acetylcholinesterase inhibitors and gabaa inverse agonists for the treatment of cognitive disorders
03/20/2003WO2002024897A9 Conditionally replicating viral vectors and their use
03/20/2003WO2002020032A9 Stat3 agonists and antagonists and therapeutic uses thereof
03/20/2003WO2002012245B1 Azabicyclic derivatives and their therapeutic use
03/20/2003WO2002012188B1 Indole compounds useful for the treatment of cancer
03/20/2003WO2002002089A3 Anthelmintics for preventing parasitic infections in humans and animals
03/20/2003WO2001087913A9 Method for treating retinal degeneration with purinergic receptor agonists
03/20/2003WO2001073104A9 Beta-glucans from filamentous fungi
03/20/2003WO2001072341A3 Methods of treating neoplasia with combinations of target cell-specific adenovirus, chemotherapy and radiation
03/20/2003US20030056240 Transgenic animal model for use in the treatment of diabetes
03/20/2003US20030056239 NMP35 apoptosis inhibitor gene disruptions, compositions and methods related thereto
03/20/2003US20030055307 Devices for detection and therapy of atheromatous plaque
03/20/2003US20030055286 Il-8 receptor antagonists
03/20/2003US20030055275 Prevention of neutrophil recruitment
03/20/2003US20030055265 Oxazole derivatives
03/20/2003US20030055261 Compounds with growth hormone releasing properties
03/20/2003US20030055260 Il-8 receptor antagonists
03/20/2003US20030055258 New crystal modification of torasemide
03/20/2003US20030055250 Pteridine compounds for the treatment of psoriasis
03/20/2003US20030055248 Il-8 receptor antagonists
03/20/2003US20030055246 Serine protease inhibitors
03/20/2003US20030055245 Kinetic resolution of a intermediate useful in the production of benazepril and analogues thereof
03/20/2003US20030055244 Pyridyl-containing spirocyclic compounds as inhibitors of fibrinogen-dependent platelet aggregation
03/20/2003US20030055227 Process for obtaining lignan
03/20/2003US20030055226 Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
03/20/2003US20030055216 Nucleotide sequences coding polypeptide for use in the treatment of tumors
03/20/2003US20030055114 Methods and compositions for inhibiting the proliferation of prostate cancer cells
03/20/2003US20030055113 Copper chelators for treating ocular inflammation
03/20/2003US20030055112 Dissolving sertraline hydrochloride in a suitable solvent; removing the solvent; drying to form sertraline hydrochloride
03/20/2003US20030055111 For use in preparation of medicaments for the treatment of tumors and rheumatoid arthritis
03/20/2003US20030055110 Retinoid compounds suited for antibacterial applications
03/20/2003US20030055109 Stability
03/20/2003US20030055107 Forms of pharmaceutically active agents and method for manufacture thereof
03/20/2003US20030055106 Using potassium bisperoxo(1,10-phenanthroline)oxovanadate, potassium bisperoxo(pyridine-2-carboxylato) oxovanadate and potassium bisperoxo(2,2'-bipyridyl) oxovanadate for preventing or arresting angiogenesis in animals
03/20/2003US20030055105 Anticancer agents, perfumes or foods and drinks containing omega-hydroxyfatty acids
03/20/2003US20030055103 Utilization of achyrocline satureoides ("Marcela") extracts and liposomal preparations of natural and semi-synthetic flavonoids for the prevention and treatment of the consequences of stroke and neurodegenerative diseases
03/20/2003US20030055102 For therapy of allergic or inflammatory disorders of the eye and nose
03/20/2003US20030055101 Use of statins to inhibit formation of osteoclasts
03/20/2003US20030055099 For therapy of anoxic/hypoxic damage (e.g., cardiopulmonary resuscitation, drowning), traumatic brain injury, spinal cord injury, local anesthetic-induced seizure activity, ischemic stroke, ischemic neurodegeneration of retina, epilepticus
03/20/2003US20030055098 Method of treatment
03/20/2003US20030055097 Indazolyl-substituted pyrroline compounds as kinase inhibitors
03/20/2003US20030055096 For agricultural and horticultural use
03/20/2003US20030055095 Administering to the patient a therapeutically effective amount of a compound that is an MEK inhibitor for inhibiting neutrophil migration
03/20/2003US20030055093 For therapy of cardiovascular diseases, stable or unstable angina pectoris, coronary heart disease, stable or unstable angina pectoris, coronary heart disease, Prinzmetal angina, acute coronary syndrome, heart failure, myocardial infarction
03/20/2003US20030055092 Remedies for ischemic stroke
03/20/2003US20030055091 Combination therapy comprising glucose reabsorption inhibitors and retinoid-X receptor modulators
03/20/2003US20030055089 Endoparasiticidal and ectoparasiticidal agents
03/20/2003US20030055088 Aryl substituted pyridines and the use thereof
03/20/2003US20030055087 As analgesic
03/20/2003US20030055086 Amino acid derivatives and use thereof as nep, ace and ece inhibitors
03/20/2003US20030055083 Method of providing an antihistaminic effect in a hepatically impaired patient
03/20/2003US20030055080 Quinuclidine derivatives and their use as muscarinic M3 receptor ligands
03/20/2003US20030055078 Use of phanquinone for the treatment or prevention of memory impairment
03/20/2003US20030055077 Method and compositions for the treatment of allergic conditions using pgd2 receptor antagonists
03/20/2003US20030055075 Useful for administering opioids compound such as fentanyl by injection; for reducing unwanted diversion of narcotics
03/20/2003US20030055074 For use in therapy of psychic and neurological disorders
03/20/2003US20030055073 Remedies for sjoegren's syndrome
03/20/2003US20030055072 Methods of inhibiting Pin1-associated states using a fredericamycin a compound
03/20/2003US20030055071 For therapy, prophylaxis or delaying the onset of AIDS and infection by HIV
03/20/2003US20030055070 Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of selective serotonin reuptake inhibitor (SSR) induced sexual dysfunction
03/20/2003US20030055068 Pyrazole compounds useful as protein kinase inhibitors
03/20/2003US20030055067 For therapy and prophylaxis of fungal infections
03/20/2003US20030055065 Administering tricyclic amide and urea compounds for inhibiting the abnormal growth of cells
03/20/2003US20030055064 Piperazine compounds and medicinal use thereof
03/20/2003US20030055062 Heteroaryl urea neuropeptide Y Y5 receptor antagonists
03/20/2003US20030055061 Therapy of disease or condition which is caused by a disorder of the serotonin system by administering 2,7-substituted octahydro-1H-pyrido(1,2-a)pyrazine derivatives, and their acid addition salts
03/20/2003US20030055060 Imidazo-triazine derivatives as ligands for GABA receptors
03/20/2003US20030055058 Administering to a mammal an angiotensin converting enzyme inhibitor and a protein-tyrosine phosphatase inhibitor for improving the cardiovascular risk profile
03/20/2003US20030055056 For use as antitumor and immune suppressive agents, as inhibitors of proliferative cell growth and as prophylactic agents to inhibit and prevent cancer and non-malignant cell growth
03/20/2003US20030055055 For inducing and maintaining anesthesia, sedation and muscle relaxation, as well as for combating febrile convulsions in children
03/20/2003US20030055054 CXCR3 antagonists
03/20/2003US20030055051 Having anti- inflammatory effect, which is less irritant, which has high safety and storage stability
03/20/2003US20030055050 CRF receptor antagonists and methods relating thereto
03/20/2003US20030055049 For therapy of abnormal cell growth, such as cancer, in mammals
03/20/2003US20030055048 Compositions and methods for treating or preventing convulsions or seizures
03/20/2003US20030055047 For prevention and/or suppression of preterm labor, suppression of labor at term prior to caesarean delivery, and for the treatment of dysmenorrhea; useful in enhancing fertility rates
03/20/2003US20030055046 Novel pyrido cyclohexenyl phenyl carboxamides tocolytic oxytocin receptor antagonists
1 ... 5528 5529 5530 5531 5532 5533 5534 5535 5536 5537 5538 5539 5540 5541 5542 5543 5544 5545 5546 5547 5548 ... 7860